Nifty Pharma Drops US Levy Threatens

  Published 8 months ago

Nifty Pharma slides 1.64% to 21,617.25, marking a five‑session decline amid US levy threats for generics.

  • Top losers include Natco Pharma (3.42%), Laurus Labs (3.32%), Abbott India (2.63%), and Gland Pharma (2.56%).
  • Generic manufacturers are exempt from levies, sustaining low‑cost export revenues to the United States market currently.
  • White House urges onshoring; Trump warns levies could soar up to 200% without localized production.

You might like these

Ather & Infineon Partner for India's EV Future

Rajasthan Rs 3,700 Crore Project Launch

RBI Bank Credit Data, April 2025

Vipul Organics Expands into Automotive Chemicals with New Compound

Swiggy, Eternal Rally on Margin Hopes

India Sugar Surplus to Boost Exports in 2025/26

DLF Eyes Mumbai Luxury Project

News that matters the most ⚡